SAN DIEGO, CA, Oct. 4 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the expansion of its recently formed Clinical and Scientific Advisory Board (CSAB), adding three members with experience directly relevant to the Company's development programs, including its lead HspE7 clinical program for human papillomavirus (HPV)-related diseases.
Strengthening its already robust CSAB, these distinguished advisors add even more depth in the fields of immunology and clinical research in HPV-related diseases. The new members include:
Commenting on the expansion, Gregory M. McKee, Nventa's President and Chief Executive Officer stated: "We feel very fortunate to be in a position to attract such a prestigious group of experts. These additional members complement our existing team nicely and we expect that they will provide outstanding guidance as we continue to advance our HspE7 and other programs forward."
About Nventa Biopharmaceuticals Corporation:
--------------------------------------------
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945, dslade@nventacorp.com
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive,
Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,
dslade@nventacorp.com
